The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19

Clinical and Translational Science ◽

10.1111/cts.13213 ◽

2022 ◽

Author(s):

Alexander P. J. Vlaar ◽

Endry H. T. Lim ◽

Sanne Bruin ◽

Simon Rückinger ◽

Korinna Pilz ◽

...

Download Full-text